Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 11Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neoplasm Metastasis 9Leukemia 9Neoplasms 8Myelodysplastic Syndromes 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Lymphoma, Non-Hodgkin 7Leukemia, Myeloid, Acute 7Carcinoma, Renal Cell 7Prostatic Neoplasms 6Melanoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Recurrence 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Graft vs Host Disease 5Advanced Cancer 5Unspecified Adult Solid Tumor, Protocol Specific 4Primary Myelofibrosis 4Pancreatic Neoplasms 4Neoplasms, Plasma Cell 4Myeloproliferative Disorders 4Lung Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Glioblastoma 4

Interventions

Amifostine 4Filgrastim 3Cyclophosphamide 3Melphalan 2Irinotecan 2Cytarabine 2Carboplatin 2spartalizumab 1sodium thiosulfate 1sargramostim 1lometrexol 1etoposide phosphate 1Vincristine 1Temozolomide 1Sirolimus 1Procarbazine 1Phenobarbital 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Mannitol 1Lomustine 1Interleukin-2 1Idarubicin 1Genetic Therapy 1Gemcitabine 1Folic Acid 1Fibroblast Growth Factor 7 1Fecal Microbiota Transplantation 1Drug Therapy 1Deoxycytidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Drug-Related Side Effects and Adverse Reactions × Sirolimus × Clear all
NCT00317798 2011-08-30

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

University of Rochester

Phase 1 Completed
18 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡